UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 567.1	$ 678.3
Short-term investments	50.0	6.6
Accounts receivable, net	329.9	362.2
Inventories	695.9	577.2
Other current assets	183.2	172.0
Total current assets	1,826.1	1,796.3
Property, plant and equipment, net	354.6	306.1
Goodwill	312.8	293.0
Operating lease assets	60.7	65.6
Intangibles, net and other long-term assets	325.2	310.5
Total assets	2,879.4	2,771.5
Current liabilities:
Current portion of long-term debt	1.7	0.5
Accounts payable	113.9	118.4
Customer advances	154.6	137.9
Other current liabilities	413.0	388.8
Total current liabilities	683.2	645.6
Long-term debt	828.2	812.8
Operating lease liabilities	42.1	47.0
Other long-term liabilities	363.2	327.9
Commitments and contingencies (Note 13)
Redeemable noncontrolling interest		21.1
Shareholders' equity:
Preferred stock, $0.01 par value 5,000,000 shares authorized, none issued or outstanding
Common stock, $0.01 par value 260,000,000 shares authorized, 173,872,664 and 173,502,375 shares issued and 153,184,527 and 154,155,798 shares outstanding at September 30, 2020 and December 31, 2019, respectively	1.7	1.7
Treasury stock, at cost, 20,688,137 and 19,346,577 shares at September 30, 2020 and December 31, 2019, respectively	(598.8)	(543.8)
Accumulated other comprehensive income	(5.2)	(25.5)
Other shareholders' equity	1,554.4	1,474.4
Total shareholders' equity attributable to Bruker Corporation	952.1	906.8
Noncontrolling interest in consolidated subsidiaries	10.6	10.3
Total shareholders' equity	962.7	917.1
Total liabilities and shareholders' equity	$ 2,879.4	$ 2,771.5